Effects of 5 weeks treatment with dapagliflozin in type 2 diabetes patients on how the hormone insulin acts on sugar uptake in muscles.

Trial Identifier: D1690C00047
Sponsor: AstraZeneca
NCTID:: NCT03338855
Start Date: March 2018
Primary Completion Date: November 2019
Study Completion Date: November 2019
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
Dutch Translation

Trial Locations

Country Location
Netherlands Maastricht, Netherlands, 6229 ER